Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)

Lynn Mara Schuchter, Ragini Reiney Kudchadkar, Rene Gonzalez, Donald P. Lawrence, Jeffrey Alan Sosman, Jeffrey R. Infante, Adil Daud, Richard Kefford, Jonathan S. Cebon, William Howard Sharfman, Ravi K. Amaravadi, Peter D. Boasberg, Karl D. Lewis, Keith Flaherty, Danielle Ouellet, Shonda M. Little, Jennifer Clark, Geoffrey Thomas Gibney, Kiran Patel, Omid Hamid

Research output: Contribution to journalMeeting abstractpeer-review

Fingerprint

Dive into the research topics of 'Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation in combination with the MEK1/2 inhibitor trametinib (T) in patients (pts) with BRAF mutation-positive metastatic melanoma (MM)'. Together they form a unique fingerprint.

Medicine & Life Sciences